Plasma Rich in Growth Factors (PRGF-Endoret)in the Treatment of Androgenetic Alopecia

A Pilot Randomized, Double-blind, Placebo-controlled Clinical Trial to Obtain Preliminary Data on Efficacy and Safety in the Application of PRGF-Endoret by Mesotherapy, in the Treatment of Male and Female Androgenetic Alopecia of Over 6 Months Duration.

• Androgenetic alopecia (AGA) or common baldness is the most common cause of hair loss in both men and women and is caused by the action of androgens in genetically predisposed individuals.
• This clinical trial was designed to evaluate the efficacy and safety of using a preparation of autologous plasma rich in growth factors (PRGF-Endoret) in the treatment of androgenetic alopecia.

Inclusion Criteria:

• Androgenetic alopecia according to the following scales:
• Men: Hamilton/Norwood Scale: grades II-VI
• Women: Ludwig Scale grades I-II.
• Possibility of follow-up during the study

Exclusion Criteria:

• No androgenetic alopecia
• Telogen and anagen effluvium
• Active inflammation or infection in the intervention area
• Presence of active systemic infections.
• Background of cancerous or precancerous lesions.
• Background of connective or rheumatic diseases.
• Suffering from any serious blood disorders.
• To have undergone treatments for alopecia in the previous 6 months.
• Previous hair implants
• Intake of drugs that affect hair loss.
• Be undergoing immunosuppressive therapy and/or anticoagulants.
• Known intolerance to mesotherapy.
• Taking contraceptives containing cyproterone acetate.
• Pregnancy
• In general, any limitations that would prevent the proper application of both treatments and the right monitoring of the efficacy variables.